Dit is ook nog wel een interessante passage in het kader van verkoopverwachtingen in EU (uit toelichting H1 cijfers, door CFO).
And in the EU and the rest of the world, the product sales were relatively flat. These markets are very competitive. They are much lower priced; it's much harder to move the needle in those markets. We did see increased competition in certain eastern European markets which unfortunately affected our partner SOBI a little bit. And that was because of product launches by those competitive products.
At the same time, we've got limited growth from Pharming's own business, which were affected by national revenue caps which are a feature of operating in Europe. These are caps in which the national government can say well you can sell up to so much, but then you have to give 90% of your sales price back to the government, which is all very well, but it does mean that it's very hard to progress sales beyond certain numbers.
Oftewel: Europese landen romen de winst af.